Evidence map›Paper›PMID 33905793›Full record

ArticleJournal of hepatology2021

Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.

Jitao Wang, Zhiyun Hou, Jianxin Liu, Ye Gu, Yunhong Wu, Zhenhuai Chen, Jiansong Ji, Shiqi Diao, Yuanwang Qiu, Shengqiang Zou and 35 more

2 registry-linked trialsOpen access · bronzeAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 62 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 6 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05204602 unknown statusnot on this mapstarted 2022, after this paper: background citation

Safety and Immunogenicity of Third Dose SARS-CoV-2 Vaccine Booster in Patients With Liver Diseases Following Two Doses of Inactivated Vaccines (NMCID-CHESS 2201): a Multicenter Cohort Study

TypeobservationalSponsorHuashan HospitalRan2022 to 2022Enrolled1,000ConditionsCOVID-19, Vaccine Reaction, Liver Diseases
NCT05273541 phase1 / phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

Beijing 302 Hospital

TypeinterventionalSponsorBeijing 302 HospitalRan2022 to 2023Enrolled100ConditionsPatients With Cancer, Vaccine Reaction, COVID-19ArmsCoronavirus vaccination
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 6 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. [Rapid guideline for COVID-19 vaccination in patients with chronic liver diseases, hepatolbiliary malignancy and liver transplant].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2021
    Guideline
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. COVID-19 and Fatty Liver Disorders.Journal of clinical medicine · 2023
    Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

45 authors at 16 institutions in 3 countries.

Jitao WangCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China; CHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China; CHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
Zhiyun HouCHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China.
Jianxin LiuCHESS-COVID-19 Group, Jinzhou Central Hospital, Jinzhou, China.
Ye GuCHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
Yunhong WuCHESS-COVID-19 Group, Hospital of Chengdu Office, People's Government of Tibet Autonomous Region, Chengdu, China.
Zhenhuai ChenCHESS-COVID-19 Group, Baoding People's Hospital, Baoding, China.
Jiansong JiCHESS-COVID-19 Group, Lishui Central Hospital, Lishui, China.
Shiqi DiaoCHESS-COVID-19 Group, The Third People's Hospital of Linfen City, Linfen, China.
Yuanwang QiuCHESS-COVID-19 Group, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
Shengqiang ZouCHESS-COVID-19 Group, The Third People's Hospital of Zhenjiang City, Zhenjiang, China.
Aiguo ZhangCHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China.
Nina ZhangCHESS-COVID-19 Group, Jincheng People's Hospital, Jincheng, China.
Fengxian WangCHESS-COVID-19 Group, Jinzhou Central Hospital, Jinzhou, China.
Xue LiCHESS-COVID-19 Group, Jinzhou Central Hospital, Jinzhou, China.
Yan WangCHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
Xing LiuCHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
Cheng LvCHESS-COVID-19 Group, The Sixth People's Hospital of Shenyang City, Shenyang China.
Shubo ChenCHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
Dengxiang LiuCHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
Xiaolin JiCHESS-COVID-19 Group, Xingtai People's Hospital, Xingtai, China.
Chao LiuCHESS-COVID-19 Group, Hospital of Chengdu Office, People's Government of Tibet Autonomous Region, Chengdu, China.
Tao RenCHESS-COVID-19 Group, Hospital of Chengdu Office, People's Government of Tibet Autonomous Region, Chengdu, China.
Jingwei SunCHESS-COVID-19 Group, Baoding People's Hospital, Baoding, China.
Zhongwei ZhaoCHESS-COVID-19 Group, Lishui Central Hospital, Lishui, China.
Fazong WuCHESS-COVID-19 Group, Lishui Central Hospital, Lishui, China.
Fenxiang LiCHESS-COVID-19 Group, The Third People's Hospital of Linfen City, Linfen, China.
Ruixu WangCHESS-COVID-19 Group, The Third People's Hospital of Linfen City, Linfen, China.
Yan YanCHESS-COVID-19 Group, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
Shiliang ZhangCHESS-COVID-19 Group, The Fifth People's Hospital of Wuxi, Affiliated Hospital of Jiangnan University, Wuxi, China.
Guohong GeCHESS-COVID-19 Group, The Third People's Hospital of Zhenjiang City, Zhenjiang, China.
Jiangbo ShaoCHESS-COVID-19 Group, The Third People's Hospital of Zhenjiang City, Zhenjiang, China.
Shiying YangDepartment of Hepatology, The First Hospital of Lanzhou University, Lanzhou, China.
Chuan LiuCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
Yifei HuangCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
Dan XuCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
Xiaoguo LiCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
Jingwen AiDepartment of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, China.
Qing HeNational Clinical Research Center for Infectious Diseases, The Third People's Hospital of Shenzhen, Shenzhen, China.
Ming-Hua ZhengNAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Liting ZhangDepartment of Hepatology, The First Hospital of Lanzhou University, Lanzhou, China.
Qing XieDepartment of Infectious Disease, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Don C RockeyDigestive Disease Research Center, Medical University South Carolina, Charleston, South Carolina, USA.
Jonathan A FallowfieldCentre for Inflammation Research, University of Edinburgh, Edinburgh, UK.
Wenhong ZhangDepartment of Infectious Disease, Huashan Hospital Affiliated to Fudan University, Shanghai, China. Electronic address: zhangwenhong@fudan.edu.cn.
Xiaolong QiCHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China. Electronic address: qixiaolong@vip.163.com.
First Hospital of Lanzhou University · CNHebei Medical University · CNJinzhou Central Hospital · CNThe Sixth People's Hospital of Shenyang · CNTibet Autonomous Region People's Hospital · CNJiangsu University · CNLishui Central Hospital · CNWuxi Fourth People's Hospital · CNZoucheng People's Hospital · CNBaoding People's Hospital · CNFudan University · CNCentre for Inflammation Research · GBMedical University of South Carolina · USShanghai Jiao Tong University · CNShenzhen Third People’s Hospital · CNWenzhou Medical University · CN

Funding

The role of SMAD1 and SATB2 in colon patterningP20GM130457 · NIGMS · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI Hailong Zhang · 2020 to 2026
$18.7M
Proteomics CoreP30DK123704 · NIDDK · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI DON C. ROCKEY · 2020 to 2026
$8.8M
NIDDK NIH HHS P30 DK123704NIGMS NIH HHS P20 GM130457
6 · The paper itself

Abstract

BACKGROUND &

aimsThe development of COVID-19 vaccines has progressed with encouraging safety and efficacy data. Concerns have been raised about SARS-CoV-2 vaccine responses in the large population of patients with non-alcoholic fatty liver disease (NAFLD). The study aimed to explore the safety and immunogenicity of COVID-19 vaccination in NAFLD.

methodsThis multicenter study included patients with NAFLD without a history of SARS-CoV-2 infection. All patients were vaccinated with 2 doses of inactivated vaccine against SARS-CoV-2. The primary safety outcome was the incidence of adverse reactions within 7 days after each injection and overall incidence of adverse reactions within 28 days, and the primary immunogenicity outcome was neutralizing antibody response at least 14 days after the whole-course vaccination.

resultsA total of 381 patients with pre-existing NAFLD were included from 11 designated centers in China. The median age was 39.0 years (IQR 33.0-48.0 years) and 179 (47.0%) were male. The median BMI was 26.1 kg/m

conclusionsThe inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD. LAY SUMMARY: The development of vaccines against coronavirus disease 2019 (COVID-19) has progressed rapidly, with encouraging safety and efficacy data. This study now shows that the inactivated COVID-19 vaccine appears to be safe with good immunogenicity in the large population of patients with non-alcoholic fatty liver disease.

Indexed as

COVID-19Non-alcoholic Fatty Liver DiseaseVaccinationVaccines, InactivatedAdultAntibodies, NeutralizingAntibodies, ViralChinaCOVID-19 VaccinesFemaleHumansImmunogenicity, VaccineMaleOutcome Assessment, Health CareSARS-CoV-2Antibodies, NeutralizingAntibodies, ViralCOVID-19 VaccinesVaccines, Inactivated

Identifiers

PMID33905793
PMCPMC8185617
OpenAlexW3158339801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.